Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2019 Earnings Conference Call - Final Transcript
Nov 06, 2019 • 04:30 pm ET
Greetings, and welcome to the Clearside Biomedical's Third Quarter 2019 Financial Results and Corporate Update Conference Call. As a reminder, this conference call is being recorded.
I would now like to introduce your host, Jenny Kobin, Clearside Investor Relations. Please go ahead.
Good afternoon, everyone, and thank you for joining us on the call today. Before we begin, I would like to remind you that during today's call, we will be making certain forward-looking statements. Various remarks that we make during this call about the Company's future expectations, plans and prospects constitute forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31st, 2018, our quarterly report on Form 10-Q for the quarter ended June 30th, 2019, and our other SEC filings available on our website.
In addition, any forward-looking statements represent our views as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so even if our views change.
On today's call, George Lasezkay, our Chief Executive Officer and member of the Board of Directors, will provide a strategic update; Dr. Thomas Ciulla, our Chief Medical Officer, will provide R&D highlights; and Charlie Deignan, our Chief Financial Officer, will provide a financial summary. We will then open the call for your questions. Brion Raymond, our Chief Commercial Officer, is also with us today and available for Q&A.
I would now like to turn the call over to George.
Thank you, Jenny. Good afternoon, everyone, and thank you for joining us on the call today. I'm pleased to report that we have made meaningful progress on our overall corporate strategy to broaden the reach of our suprachoroidal space injection platform. A component of this strategic plan is the establishment of key external collaborations.
Over the last three months, we have secured three significant partnerships that validate and will potentially expand the reach of our suprachoroidal injection platform. Two weeks ago, we announced that Bausch Health and its Ophthalmic division, Bausch + Lomb, acquired an exclusive license for the commercialization and development of XIPERE in the United States and Canada.
As a reminder, XIPERE is our proprietary suspension of triamcinolone administered suprachoroidally with our SCS microinjector for the treatment of macular edema associated with uveitis. We are thrilled to have licensed XIPERE to such a high-quality organization with a well-established and well-regarded presence in the ophthalmology community.
Bausch has the right to pursue development and commercialization of XIPERE for additional ophthalmic indications. And they also have the right to develop and commercialize our proprietary SCS microinjector in combination with certain other specified corticosteroids and non-steroidal anti-inflammatory drugs in the field of ophthalmology.